Abstract: Diabetes is a major cause of mortality worldwide. There are several types of diabetes, with type 2 diabetes mellitus (T2DM) being the most common. Many factors, including environmental and genetic factors, are involved in the etiology of the disease. Numerous studies have reported the role of genetic polymorphisms in the initiation and development of T2DM. While genome-wide association studies have identified around more than 200 susceptibility loci, it remains unclear whether these loci are correlated with the pathophysiology of the disease. The present review aimed to elucidate the potential genetic mechanisms underlying T2DM. We found that some genetic polymorphisms were related to T2DM, either in the form of single-nucleotide polymorphisms or direct amino acid changes in proteins. These polymorphisms are potential predictors for the management of T2DM.
Introduction
Diabetes is a chronic disease that can lead to serious complications. It is classified into two main types: type 1 diabetes mellitus and type 2 diabetes mellitus (T2DM). T2DM is a metabolic disorder that is characterized by peripheral insulin resistance and impaired insulin secretion. 1 During the period from 1980 to 2008, the number of people worldwide with T2DM has more than doubled. 2 Studies on the prevalence of diabetes in the adult population aged 20-79 years estimated that the worldwide prevalence of people with T2DM was 6.4% in 2010, where 285 million adults had T2DM. By 2030, 439 million adults are predicted to have T2DM, accounting for 7.7% of the adult population worldwide. 3 Environmental and genetic factors are involved in the pathogenesis of T2DM. 4 The majority of genes involved play a role in β-cell function. Genetic polymorphisms that have impacts on important proteins that participate in glucose metabolism and insulin secretion may also affect susceptibility to T2DM. 5 Genome-wide association studies (GWASs), the candidate gene approach, and linkage analysis have identified various genes that contribute to T2DM susceptibility. [6] [7] [8] The development of genetic risk scores using combined analysis of loci has significantly contributed to predicting the incidence of T2DM. [9] [10] [11] Therefore, it is possible to facilitate early diagnosis and determine preventative strategies to reduce the incidence of the disease. [12] [13] [14] [15] T2DM has a strong genetic basis, and individuals with a first-degree family history are at increased risk of developing the disease, and this risk is increased twofold if both parents have diabetes. 16 Several risk factors for T2DM have been previous study showed that KLF14 is involved in metabolism as a transcriptional activator as it regulates the gene networks that participate in lipid metabolism. 64 KLF14
gene is assumed to be an ancient retrotransposed copy of KLF16 gene, presumably after the divergence between eutherians and marsupials 65, 66 due to its lack of introns and a high sequence homology with KLF16 gene. The maternal expression of KLF14 was associated with an increased risk of T2DM when carried on the maternal chromosome. 67 The expression of KLF14 in adipose tissue was shown to be associated with a combined insulin resistance phenotype. It is characterized by increased fasting insulin and triglyceride levels and decreased HDL-cholesterol levels. 68 Higher fasting insulin levels are manifested in the risk allele of rs4731702, 67 such that the risk allele of this non-coding genetic variant could play a role in insulin resistance. Furthermore, it may act to influence the expression of genes associated with the body mass index (BMI) and the homeostasis model assessment for insulin resistance (HOMA-IR) due to its primary effects on insulin sensitivity, fasting glucose, and adiponectin. 69 Moreover, rs4731702
was reported to be associated with gene expression in subcutaneous adipose tissue biopsies. 68 Hence, it was suggested that KLF14 is the master transregulator of adipose tissue gene expression. 70 One study also revealed that the G allele of KLF14 (rs972283) contributes to elevated blood pressure. Therefore, patients with metabolic syndrome have a greater risk of cardiovascular disease.
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KCNQ1
The KCNQ1 gene, which encodes the alpha-subunit of voltage-gated potassium channel Kv7.1, is a member of the Kv channel superfamily, and is located on chromosome 11p15.5. 71, 72 The protein that KCNQ1 gene encodes is the pore-forming alpha subunit of KCNQ1/KCNE1, KCNQ1/ KCNE2 and KCNQ1/KCNE3 potassium channels. 73 The expression of KvLQT1 repolarizes the action potential in cardiac muscles. 20 KCNQ1 is also expressed in other tissues such as adipose tissue, the pancreas, and the brain. 74 Mutations in KCN genes are associated with the development of diabetes. Variants in the KCNQ1 gene have been associated with reduced depolarization-evoked insulin exocytosis. 24 The variant allele (C allele) of the rs2283228 Chinese She T/C [32] Chinese T/C [33] Uyghur T/C [34] Han Chinese T/C [35] (Continued) 75 Moreover, previous studies showed that a vast majority of the genomic loci detected to date were associated with β-cell dysfunction in patients with T2DM. [76] [77] [78] KCNQ1 is expressed in pancreatic islets and plays an essential role in glucose homeostasis as it functions as a regulator of insulin secretion. 71, 72 The KCNQ1 protein was shown to be expressed in insulin-secreting INS-1 cells. 79 A study showed that the C allele of the intronic rs2237895 in KCNQ1 was associated with a decreased risk of abdominal obesity in patients with T2DM. These findings indicated that the C allele of rs2237895 is correlated with a decreased BMI and waist circumference in a Chinese population.
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DUSP9
DUSP9 encodes dual-specificity phosphatase 9 [also known as map kinase phosphatase 4 (MKP4)], mapped on chromosome X, with a cytogenetic location at Xq28. It is expressed in various tissues such as adipose tissue, muscles, insulin-responsive tissues, and the liver. DUSP9 plays important roles in regulating cell cycle and insulin action, and also has protective effects against the development of insulin resistance due to its ability to inactivate extracellular signal-regulated kinase and c-Jun N-terminal kinase. Therefore, DUSP9 was considered as a stressinduced insulin resistance mediator. 83, 84 While the effects of DUSP9 on insulin metabolism may differ depending on conditions and tissues, it is considered an important regulator of insulin sensitivity.
25
The study of Voight et al 62 
FTO
Biological function of FTO (fat-mass and obesity associated) modulates the gene expression through methylation-demethylation modification since FTO is part of Fe(II)-and 2-oxoglutarate-dependent dioxygenases superfamily. Therefore, ubiquitously expressed hepatic FTO showed an important role in the homeostasis of glucose and lipid. [85] [86] [87] [88] [89] Many studies have demonstrated a strong association between the FTO gene and the incidence of obesity, which is a major risk factor for T2DM. [90] [91] [92] [93] [94] [95] [96] The majority of people with T2DM, particularly those of East Asian ethnicities, achieve their maximum lifetime BMI (BMI max ) at the time of or before the onset of disease, and after T2DM diagnosis. The BMI max may also be reached after lifestyle interventions such as diet and exercise, and/or treatment with various antidiabetic medicines that may affect their obesity-related measurements, such as the BMI. 97, 98 A previous study has reported that the BMI max was strongly associated with an increased risk of T2DM. FTO SNPs were significantly correlated with the BMI max in a sexstratified analysis. 28 The study also found that rs1558902 was correlated with the incidence of T2DM in humans, and the correlations between SNPs and T2DM remained significant after the adjustment for the current age and BMI. Furthermore, Hertel et al also reported that adjusting the FTO variant for the waist-to-hip ratio and waist circumference conferred an increased risk of T2DM. 29 Decreased mitochondrial oxidative capacities, oxidative stress, and lipid accumulation are suggested to increase the expression of FTO in patients with T2DM. Furthermore, the rs9939609 SNP may alter the risk of T2DM independent of the BMI by affecting other genes in the region. 99 The increased FTO expression can stimulate de novo lipogenesis, inhibit lipolysis and fatty acid oxidation, and increase gluconeogenesis, which can lead to abnormally increased triglyceride deposition and the production of hepatic glucose ( Figure 2 ).
HNF4A
The HNF4A gene is a member of the steroid hormone receptor superfamily that is mainly expressed in the kidney, liver, pancreas (including β-cells), and small intestine, and influences metabolism and lipid transport. 100, 101 It also plays roles in liver function and hepatocyte differentiation.
102,103
The HNF4A gene is composed of 13 exons and two promoters, known as P1 and P2. 104 The P1 promoter is active mainly in liver cells, [104] [105] [106] while the P2 promoter is the major splice variant in pancreatic β-cells.
107−109
Approximately 1-2% of all diabetes cases are the monogenic form, known as maturity-onset diabetes of the young (MODY). 110 It is characterized by an early age of onset (usually during adolescence or childhood), dominant inheritance, and defects in β-cell function. MODY resulting from mutations in the HNF4A transcription factor are known as MODY1. 111 Studies on the genetic linkage have demonstrated that MODY1 is closely related to markers near HNF4A on chromosome 20.
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The non-coding variants of HNF4A gene rs6017317 113 and rs4812829 36 and a coding missense variant rs1800961 (T130I) 114 have been shown to play a role in the development of T2DM. In pancreatic β-cells (Figure 3 ), HNF4A is required for glucose metabolism and the expression and secretion of the normal insulin gene, 115 while in the liver, HNF4A is required for hepatic gluconeogenesis. 116 It also plays a role in T2DM, which is associated with decreased insulin secretion. 123 Hence, IGF2BP2 may support T2DM development via changes in adipose tissue or impaired β-cell function. Duesing et al conducted a comprehensive genetic association study on French Caucasians and showed that IGF2BP2 rs4402960 and rs1470579 were associated with T2DM susceptibility. 124 Another study reported higher levels of fasting plasma glucose, total cholesterol, and postprandial serum insulin in patients with T2DM who carried the C allele of rs1470579 compared with patients with T2DM who were AA carriers. IGF2BP2 polymorphisms play a role in the regulation of pancreatic β-cell function. 125 Studies have also demonstrated that IGF2BP2 is strongly associated with overweight and obesity. 38 Obesity is associated with T2DM; hence, it is hypothesized that the association between IGF2BP2 and T2DM may be modified by obesity. This is also known as the interplay between IGF2BP2 and obesity with T2DM. 126 In keeping with this hypothesis, Chistiakov and co-workers, 127 reported that patients with T2DM have a more than twofold increase in IGF2BP2 expression levels in adipose tissue compared with healthy individuals. Associations between IGF2BP2 and visceral/abdominal total fat were also demonstrated in Mexican Americans and Canadian Caucasians, proposing a possible role of IGF2BP2 in insulin resistance.
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CDKN2A/B
The CDKN2A/B locus is located on chromosome 9p21.3, such that the CDKN2A gene encodes both the p16 inhibitor of cyclin-dependent kinase p16INK4A and p14ARF, and the CDKN2B gene encodes p15INK4B, 129 respectively, and this locus has been associated with T2DM risk. 43, 118 Further, the 9p21 SNP rs10811661, which was associated with the expression of a long non-coding RNA known as antisense noncoding RNA in the INK4 locus [ANRIL; also called CDKN2B antisense RNA 1 (CDKN2B-AS1)], 130 was linked with the risk of human diabetes in a GWAS. 118 Polymorphisms in CDKN2A/ B affect metabolic health related to proteins that contribute to the regulation of β-cell mass, insulin secretory function, and proliferation. 43 Additional studies in Asia and Europe have also confirmed that CDKN2A/B is associated with T2DM risk. [40] [41] [42] 44, 56, [131] [132] [133] CDKN2A/B is highly expressed in adipocytes and islet cells, as well as in brain cells. Both CDKN2A and CDKN2B are tumor suppressor genes involved in cell apoptosis, tumorigenesis, and proliferation. 134 Alterations to the phenotype of immune cells influence systemic and peripheral insulin resistance and lead to T2DM. Especially in obesity condition, macrophage infiltrates into adipose tissue and lead to develop a chronic lowgrade inflammation. These adipose tissue macrophages (ATMs) stimulate pro-inflammatory cytokines secretion and further will contribute to insulin resistance. 135 Additionally, CDKN2A/B-ANRIL gene products control glucose homeostasis, in part, via the control of insulin secretion and β-cell function (Figure 4 ).
TCF7L2
TCF7L2 (transcription factor 7-like 2) is a transcription factor that plays a role in the Wnt-signaling pathway, which regulates pancreatic islet cell functions, such as proliferation and cell survival. 136 A previous study showed that increased β-cell apoptosis was associated with decreased TCF7L2 activity, resulting in the downregulation of insulin secretion.
137,138
The TCF7L2 gene is located on chromosome 10q.25.2-25.3, also known as the TCF4 locus. Previous studies have indicated that people with T2DM are more likely to carry the genetic variant (rs7903146) of this gene. [139] [140] [141] Furthermore, studies on various ethnic populations have shown that mutations of this gene are associated with TCF7L2 in a selfregulating manner via transcriptional protein complex binding across rs7903146.
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The Wnt-signaling pathway also controls the transcription of the proglucagon gene, which regulates incretin hormones such as glucagon-like peptide-1 that inhibits glucagon activity and maintains food mobility from the stomach to the duodenum, and gastric inhibitory polypeptide that is produced by intestinal K cells. Mutations in TCF7L2 also result in reduced expression of the proglucagon gene and, consequently, reduced glucagon-like peptide-1 production. [145] [146] [147] TCF7L2 is expressed in other organs, such as skeletal muscle, gut, fat, and liver, which are all also involved in mediating metabolic homeostasis. 148 The overexpression of β-catalase produced reciprocal effects on hepatic gluconeogenesis. 149 On the other hand, the Wnt-signaling pathway negatively regulates adipogenesis, and Wnt ligands produced by adipocytes may also function as endocrine and paracrine factors. 150 Based on those studies, the possible roles of TCF7L2 in the pathogenesis of T2DM are summarized in Figure 5 .
KCNJ11
The KCNJ11 gene (potassium channel, inwardly rectifying, subfamily J, member 11) encodes the Kir6.2 protein (inward-rectifier potassium ion channel), which is important for insulin secretion via the ATP-sensitive potassium (K ATP ) channel. It has no intron region and is located on chromosome 11p15.1. 151 As described in Figure 6 
Antioxidant Genes
Disruption to the balance of antioxidants and reactive oxygen species (ROS) results in increased oxidative stress, which may lead to diabetes. The generation and accumulation of ROS in β-cells can cause β-cell dysfunction, defects in insulin production, and impaired function, which result in diabetes. 157 However, the impact of oxidative stress can be reduced or modified by enzymatic antioxidants, including catalase (CAT), glutathione-S-transferase (GST), glutathione peroxidase (GPx), superoxide dismutase (SOD), nitric oxide synthase, and nicotinamide adenine dinucleotide phosphate oxidase. [158] [159] [160] Banerjee et al reported that individuals with a polymorphism affecting the genetic regulation of these six enzymes were at increased risk of developing T2DM. Known polymorphisms in these genes include GSTM1del, GSTT1del, GSTP1 105I/V(+313A/G), CAT-21A/T, SOD2 + 47C/T, and GPx1 + 599C/T. 161 Banerjee and co-workers also concluded that the risk of developing T2DM increases as the variation of the genes that regulate antioxidant enzyme increases.
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DNAJC3
As explained by DNAJC3 is an endoplasmic reticulum (ER) lumen protein and a member of the HSP70 family.
It is located in all tissues in humans (predominantly the liver and pancreas), and plays a role in maintaining homeostasis in the ER. 54 It serves as co-chaperone of binding immunoglobulin protein (BiP) during the unfolded protein response (UPR), which is an ER adaptive signaling pathway. Normally, the ER regulates membrane homeostasis by synthesizing and modifying secretory and membrane proteins. 54 However, when cells are exposed to abnormal conditions, such as infection, homeostasis imbalance, glucose deprivation, or stimulation that leads to ER protein overproduction, the proteins undergo incomplete or abnormal processes that form unfolded or misfolded proteins. The accumulation of these proteins increases stress in the ER lumen, eventually triggering the UPR in the ER. 54 Three pathways were reported to generate the UPR signaling pathway, including activation of transcription factor-6; 162 activation of inositol-requiring transmembrane kinase/endoribonuclease 1; 163 and double-stranded RNAdependent protein kinase-like eukaryotic initiation factor 2α kinase (PERK). 164 The UPR pathways will reduce the ER stress and maintain the cell survival by correcting the misinterpreted protein. This can be carried out by the SIL1 protein, which interacts with BiP and binds the misinterpreted protein. DNAJC3 acts prior to protein correction. It binds reversibly to hydrophobic segments of the protein and delivers it to the chaperone, BiP.
54 DNAJC3 is involved in the PERK pathway, collaborating with the chaperone, BiP, and SIL1 protein, a nucleotide exchange factor. 54 DNAJC3 mutations, such as deletions and stop mutations, result in reduced or absent binding between BiP and unfolded or misfolded proteins. 54 In summary, adaptive response failure leads to unsuccessful pancreatic ER homeostasis and cell death; and in pancreatic cell death, particularly in the pancreatic islet, this will reduce insulin production. Therefore, mutations in the DNAJC3 gene are correlated with diabetes. 54 
PGC-1α
PGC-1α (peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α) is a transcription coactivator that is involved in various biological responses, such as temperature adaptation, energy homeostasis in the mitochondria, glucose metabolism, triglyceride homeostasis, and heart development. 165 In humans, the PPARGC1A gene is located on chromosome 4 and encodes a 798-amino acid protein PGC-1α, which is expressed in most tissues with highly active mitochondria and oxidative metabolism, such as the heart, skeletal muscle, and brown adipose tissue. 166 The PGC-1α gene can convert muscle fiber type and stimulate fatty acid oxidation, thus may lead to a decreased fatty acid concentration in muscles. 167 In contrast, a recent study showed that insulin-resistant skeletal muscle and the liver were associated with increased levels of triglycerides.
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A previous study by Kelley and co-workers suggested that a decrease in mitochondrial oxidative enzymes leads to defects in the mitochondrial fatty acid oxidation pathway and, ultimately, diabetes. Furthermore, the study also observed that patients with T2DM showed downregulated expression of PPARGC1A gene. 169 
ADIPOQ
The ADIPOQ gene encodes adiponectin, which is an adipocytokine. The adipose tissue plays an important role in the development of diabetes mellitus and obesity. 170 Adiponectin, a major adipocyte secretory protein in human plasma, functions as a regulator of energy and is involved in glucose tolerance. 171 The ADIPOQ gene is located on human chromosome 3q27 and is reported to be a susceptibility locus for T2DM. 172, 173 Adiponectin is associated with increased insulin sensitivity, reduced ER stress, and increased fatty acid oxidation.
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Its functions are mediated by its receptors, AdipoR1 and AdipoR2. The binding of adiponectin to its receptor activates intracellular signaling molecules that play important roles in lipid and carbohydrate metabolism. 175 Li et al reported ADIPOQ gene polymorphisms in rs1501299, rs182052, and rs7627128 in a Chinese population, and showed a significant association with T2DM. Furthermore, a haplotype-based case-control study on the association between T2DM and the ADIPOQ gene found that the haplotypes A-A-T and G-A-T were correlated with increased potency and decreased risk of T2DM, respectively.
55
CDKAL1
Klimentidis et al reported that variations in CDKAL1 rs775480 were associated with hemoglobin A1c, which is related to T2DM. The rs775480 polymorphism is located at intron 5 of the CDKAL1 gene. 57 This SNP is associated with decreased glucose sensitivity and insulin secretion in β-cells. 176, 177 Furthermore, the rs10946398 polymorphism of the CDKAL1 gene was proposed as a marker of impaired insulin secretion, as the CC/CA genotypes and C allele contribute to T2DM susceptibility in obese individuals.
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POMC
Mutations in the POMC (pro-opiomelanocortin) gene are reportedly associated with overweight and obesity as well as the phenotype of early-onset T2DM. 58, 180, 181 POMC is a precursor polypeptide hormone that is produced in the neurons of the arcuate nucleus of the hypothalamus and plays an important role as a controller of homeostasis, as well as energy balance, food intake, and glucose metabolism.
182-184
Mencarelli et al reported that patients with T2DM and obesity related to mutations in the POMC genes showed a missense mutation in the signal peptide. 58 This mutation led to a heterozygous substitution of arginine for glycine at A15G-POMC (codon 15), which inhibited the production and secretion of the POMC protein. In humans, POMC deficiency can cause insulin resistance (hyperinsulinemia) since POMC-derived peptides have local effects on the central melanocortin pathway, and intact neuronal melanocortin signaling regulates insulin sensitivity in peripheral tissues.
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PPARγ2
PPARγ2 (peroxisome proliferator-activated receptorgamma 2) is a ligand-activated transcription factor of the nuclear hormone receptor superfamily. 187 The PPARγ2 gene plays roles in glucose homeostasis, lipid metabolism, obesity, insulin sensitivity, T2DM, and various adipocytespecific genes. 59, [188] [189] [190] Based on several case-control and family-based studies, estimated that Pro12 allele (ie, the major allele) of PPARγ was associated with a 1.25-fold elevated risk of T2DM. 191 Further, the study of Chan et al showed that the Pro12Ala polymorphism was associated with T2DM risk in the multiethnic Women's Health Initiative (WHI) Observational Study at a nominal significance level (Pro12 allele is the risk-increasing allele, p=0.01, additive model). The study was replicated in the WHI SNP Health Association Resource (WHI-SHARe) Hispanic American case-control sample (Pro12 allele is the risk-increasing allele, p=0.02, additive model). 192 Phani et al reported that the PPARγ2 gene was associated with T2DM in an obese diabetic Indian population (BMI ≥ 25 kg/m 2 ). 193 The rs1801282 polymorphism in the PPARγ2 gene has been associated with adiposity and regulation of the BMI. Furthermore, the Ala12 variant allele of rs1801282 has been shown to exhibit a decreased binding affinity to the cognate DNA element and therefore could reduce PPARγ2 transcriptional activity. 194 Based on the study of Valve et al, the Ala12 variant allele was associated with a lower BMI and a higher insulin sensitivity among normal weight and mildly obese individuals. 195 This polymorphism has also been linked to increased insulin sensitivity and protects from T2DM in Caucasian populations. 59, 193 Motavallian et al compared the allele distributions of Pro12Ala polymorphism between healthy individuals and those with diabetes. 188 They found a higher frequency of the Ala allele12 in healthy individuals than in patients with diabetes. Another study found a protective role of high Ala frequency against T2DM as it was associated with increased insulin sensitivity, while low frequency of the Ala12 allele was associated with decreased insulin sensitivity (insulin resistance), which may lead to diabetes. These findings suggest that polymorphisms in the PPARγ2 gene are associated with T2DM.
SLC30A8
Previous studies have reported that the SLC30A8 (solute carrier family 30 member 8) rs13266634 polymorphism in the major C allele was strongly associated with the risk of T2DM. 60, 61 In addition, Chang et al also reported that the SLC30A8 rs13266634 SNP was associated with age as a T2DM risk factor.
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SLC30A8 is expressed in pancreatic β-cells and encodes a zinc transporter. 196 Zinc is an important element for insulin secretion and storage. 197 Low ZnT8 (zinc transporter-protein member 8) expression leads to decreased insulin production by β-cells. Low Zn 2+ production facilitates hormone clearance by the liver (Figure 7 ). The study using ZnT8KO mice had low peripheral blood insulin levels despite hypersecretion from β cells pancreas, whilst reduced Zn 2+ production favors clearance of the hormone by liver. 32 and thus, insulin hypersecretion will occur. 200 The hypersecretion of insulin will impact the insulin sensitivity, liver clearance, and blood glucose level as the following statement, first liver will intoxicate an excessive amount of insulin. In other words, hepatic clearance will increase and liver takes more energy to function, resulting in glycogen breakdown to glucose. 201 Second, Zn 2+ also presents in insulin 202 These mechanisms will lead to an increase in blood glucose level or T2DM event.
The SLC30A8 rs13266634 polymorphism is a nonsynonymous SNP that causes an amino acid change from arginine, encoded by the C-allele, to tryptophan, encoded by the T-allele, at position 325 (Arg325Trp). This polymorphism has been linked with the development of T2DM in several populations. 31, 118, 119, 139, 140, 203, 204 T2DM risk is influenced by both genetic and environmental risk factors. Therefore, gene-environment interaction studies in T2DM could be more explored as indicated by other studies showed that a significant interaction between SLC30A8 gene rs13266634 and age in T2DM risk (p<0.0001).
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Conclusion and Future Prospects
Some genetic polymorphisms are associated with T2DM, either in the form of regulatory non-coding SNPs or as missense coding SNPs that cause direct changes to amino acids within a protein. Genes that are considered to predict or be associated with T2DM disrupt homeostasis, including insulin action and sensitivity, β-cell function and proliferation, and obesity. We realized that this review might use an incomplete searching method and some relevant papers have not been included, but it summarized genes that might be related to the development of T2DM. Moreover, studies show that different SNPs and mechanisms lead to diabetes in different ethnic groups.
Despite remarkable progress, the results from these genetic studies remain inconclusive. Therefore, future studies are required using different ethnic groups to confirm these findings globally, to determine correlations between gene expression and the mechanisms involved to confirm the suggested pathways, and to ensure that treatment of a specific gene will not have knock-on adverse effects on other genes. Thus, further intensive studies are necessary to identify more T2DM-associated genes. The evaluation and confirmation of the currently identified genes are also necessary due to conflicting findings. These polymorphisms may help to reduce the incidence and predict the risk of T2DM. Early identification may increase the prevention efficacy and increase prediabetic prognosis significantly. 
